Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Pegfilgrastim in Indolent B-Cell Lymphoma
NCT01682044Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Apr 2007
- Primary completion
- Nov 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegfilgrastim in follicular lymphoma (FL), small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), sponsored by Roswell Park Comprehensive Cancer Center. Started Apr 2007; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
follicular lymphoma (FL)small lymphocytic lymphoma (SLL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT01682044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01682044.